GeneCentric secures equity investment from Bristol-Myers Squibb Bristol-Myers Squibb to explore the use of GeneCentric’s Cancer Subtyping Platform (CSP™)
NEW YORK & DURHAM, N.C.—Bristol-Myers Squibb Company (NYSE:BMY) and GeneCentric Diagnostics, Inc. today announced a biomarker research collaboration to explore whether the application of GeneCentric’s Cancer Subtype Platform (CSP™) might be able to identify translational biomarkers for Opdivo (nivolumab), which may help inform future clinical trials. Additionally, GeneCentric announced it has secured equity funding from Bristol-Myers Squibb that will support the clinical development of GeneCentric’s CSP™ and build-out of GeneCentric’s new laboratory in Research Triangle Park.